The president of the American Academy of Sleep Medicine emphasized the need to prioritize sleep for children and the organization’s efforts to improve sleep health.
The pediatric headache specialist at NYU Langone provided an inside perspective on the effect that societal stigmas have on those with pediatric migraine and how to address those stigmas.
Mary Meskis, executive director of the Dravet Syndrome Foundation, provided a opportunities the organization is offering in honor of Dravet Syndrome Awareness Month.
Episode 21 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Michael Dobbs, MD, MHCM, of University of Texas at Rio Grand Valley. [WATCH TIME: 5 minutes]
The pair of neurologists highlight key advances needed in imaging, trial design, and preclinical modeling to drive remyelination breakthroughs in MS.
In this episode, Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.
The molecular biologist at the Cleveland Clinic Lerner Research Institute provided insight on the lingering questions about GFAP and sTREM2 astrocytes, and their immunologic correlations with Alzheimer disease and related dementias. [WATCH TIME: 4 minutes]
The executive director of Banner Alzheimer’s Institute discussed the approval of aducanumab and the potential to address unmet needs and gaps in care for patients with Alzheimer disease.
The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]
IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is optic neuritis and neuromyelitis optica spectrum disorder (NMOSD).
At AMTRD 2023, the graduate research assistant at Brown University talked about the prevalence of rapidly progressive dementia and cognition fluctuation in Parkinson disease as well as the effects of treatments for the condition. [WATCH TIME: 5 minutes]
A duo of experts highlighted the need for further studies on the exploration of how exposure to wildfire particulate matter impacts neurodegenerative diseases. [WATCH TIME: 2 minutes]
An immunology fellow at Brigham and Women’s Hospital provided perspective on the positive impacts a new diagnostic criterion for MOGAD brings to the clinical community. [WATCH TIME: 4 minutes]
The director of the Center for Brain and Mind Health at Yale University discussed new findings in thrombolytic therapy, stroke monitoring, neuroprotection, and imaging technologies presented at ESOC 2025. [WATCH TIME: 7 minutes]
A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]
The headache specialist at Jefferson Headache Center discussed the need to revamp the education process for migraine care and how much time residents spend learning about the disease. [WATCH TIME: 2 minutes]
Neurology experts discuss where BTKi’s fit in the multiple sclerosis treatment continuum.
In a paradigm with many options, once multiple sclerosis is confirmed as a patient’s diagnosis, physicians are left with 1 question: What do we choose for long-term treatment?
The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital discussed the clinical manifestations of frontotemporal dementia (FTD) and how Coya Therapeutics is moving toward precision medicine with their FTD candidate, COYA 301. [WATCH TIME: 4 minutes]
Representatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]
The professor of neurology at University of Rochester discussed a new model on how Parkinson disease may originate, highlighting potential environmental causes and progression. [WATCH TIME: 5 minutes]
The senior vice president of research at The ALS Association talked about a multidisciplinary session presented at the 2025 MDA Conference that highlighted diverse strategies for neural repair, from pharmacological targets to noninvasive brain stimulation. [WATCH TIME: 6 minutes]
SEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.
The pediatric neurologist and epileptologist at the University of Michigan's Mott Children's Hospital spoke at the 2022 AES conference about disparities that currently exist in epilepsy care. [WATCH TIME: 4 minutes]
The chief medical officer at Avidity Biosciences talked about how its exon skipping AOC therapies are designed to address the lack of functional dystrophin protein among patients with Duchenne muscular dystrophy to improve muscle function. [WATCH TIME: 4 minutes]
The research scientist from the University of Texas Medical School discussed some of the challenges and opportunities that machine learning presents in patient care.